Micronoma, the first cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, today announced the closing of $3.5 million in convertible debt financing. The contributions came from existing investor, US-based SymBiosis, LLC, and new European investor, The Seerave Foundation. The investments bring Micronoma's total amount of funding to $6.5 million since the company's first seed round six months ago.
Common genetic test often wrong when identifying rare disease-causing variants such as BRCA1 and BRCA2, study says cnnphilippines.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnnphilippines.com Daily Mail and Mail on Sunday newspapers.
Common genetic test often wrong when identifying rare disease-causing variants such as BRCA1 and BRCA2, study says
A genetic test used to detect common traits many people share is not reliable in identifying rare disease-causing variations, such as those that can predict breast and ovarian cancer, a new study has found.
The SNP test, which stands for “single nucleotide polymorphism,” is used by direct-to-consumer DNA and ancestry companies to identify common traits such as eye color, height and proclivity toward cheek dimples and dandruff, to name a few.
But when SNP tests are applied to identifying rare mutations that contribute to disease, the study found only 16% of nearly 5,000 rare mutations could be confirmed by
Local news from StateCollege.com and Centre County Partners. Read about As Students Return to Campus, Penn State Expands COVID-19 Testing, Plans for Increased Activities and more from the State College, PA region
The CDC says it's critical for schools to fully reopen, but New York officials say the state is failing when it comes to keeping students and educators safe.